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cense.Abstract G-protein coupled receptors like Bradykinin (BK) B1 represent a potential treatment
route for chronic pain and inﬂammation. Quantitative structure activity relationship has been per-
formed on a series of a-hydroxy amides as a novel class of bradykinin B1 selective antagonists, using
different physicochemical parameters along with appropriate indicator variables. It has been found
that physicochemical parameters such as connectivity indices 3v, 4v and 5v, molecular weight, molar
refractivity, density along with indicator variables are signiﬁcantly correlated with activity. In this
paper best results were obtained by using multiple regression analysis. Different models were gen-
erated with high values of R2 and low values of PRESS/SSY ratio. The signiﬁcant equations were
statistically tested by using leave one out (LOO) technique and cross validation methods.
ª 2010 King Saud University. Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Bradykinin receptor B1 (B1) is a G-protein coupled receptor
encoded by the BDKRB1 gene in humans. Its principal ligand
is bradykinin, a nine amino acid peptide generated in patho-iffmail.com (A.K. Srivastava),
. Shukla), avnipandey@rediff
iffmail.com (A. Srivastava).
y. Production and hosting by
Saud University.
lsevierphysiologic conditions such as inﬂammation, trauma, burns,
shock, and allergy. The B1 receptor is one of the two G
protein-coupled receptors that have been found to bind brady-
kinin and to mediate responses to these pathophysiologic
conditions. B1 protein is synthesized de novo following tissue
injury and receptor binding leading to an increase in the cyto-
solic calcium ion concentration, ultimately resulting in chronic
and acute inﬂammatory responses. The Bradykinin receptor is
not commonly expressed in healthy states but is automatically
induced upon injury. These receptors are expressed in central
Nervous system of mice, rats and primates. [des-Arg]BK
(DABK) and [des-Arg] kallidin are natural agonists for brady-
kinin B1 receptors, which are obtained by the metabolism of
bradykinin and kallidin.2. Methodology
QSAR studies have been done on a series a-hydroxy amides
(Wood et al., 2008). The 2D structures of the molecules were
216 A.K. Srivastava et al.drawn using Chem Sketch Software. Several physicochemical
parameters were used in the present study, which is discussed
below:
(1) Density (D) – Density is a steric parameter and calcu-
lated by ACD Lab Chem Sketch Software. This param-
eter is related with the bulk and size of the substituents.D ¼MWðMolecular weightÞ
MvðMolecular volumeÞ(2) Molecular weight (MW) – Molecular weight descriptorhas been used as a descriptor in systems such as trans-
port studies where diffusion is the mode of operation.
It is an important variable in QSAR studies pertaining
to cross resistance of various drugs in multi-drug resis-
tant cell lines (Liu et al., 1997; Holder et al., 2006;
Carton et al., 1983).
(3) Molar refractivity (MR) – Molar refractivity is gener-
ally considered to be a measure of overall bulk and is
related to London dispersion forces as follows:MR ¼ 4pNa=3
where N is Avogadro number and a is the polarizability
of the molecule. It gives no information about shape and
is generally scaled 0.1 and has been extensively used
in QSAR (Hansch et al., 1973; Bauer et al., 1960;
Srivastava and Archana, 2003).
(4) Molecular connectivity (v) Randic, 1975; Randic, 1993 –
Randic index 1v= 1v (G) of G was introduced by Ran-
dic in 1975 as the connectivity index.
(5) Indicator variables (Senda and Fujita, 1991; Ismail
et al., 2002) – These are not QSAR parameters but are
used to indicate the signiﬁcance of any particular group
or species at a particular substitution site in a given ser-
ies of drugs.3. Results and discussion
QSAR was performed on a series of 21 compounds of a-hydroxy
amides with the physicochemical parameters, which are listed
in Table 1, where the biological activity (pIC50) is a measure
of inhibitory activity. All the QSARs reported here, were de-
rived by us and were not reported in the original data set taken
from the literature as reference. We have used Hansch analysis
(Hansch and Leo, 1995; Hansch et al., 1995) for developing
these models. The QSAR multiple regression analyses were
performed with SPSS (7.5) version program. Their activity
data and the physicochemical parameters evaluated in the cor-
relation are listed in Table 2. These parameters were found to
be useful earlier in QSAR based drug modeling (Srivastava
et al., 2008, 2009a,b,c, 2010; Srivastava and Archana,
2008a,b,c; Srivastava et al., 2009; Singh et al., 2008a,b).
In order to study the role of different substituents at speciﬁc
positions indicator parameters such as I1 for H, I2 for –
CH2CH3 and I3 for –Cl at R1, R2 and R6 positions, respec-
tively were introduced and are also listed in Table 1. Multi
regression analysis of the data gave several models of which
the following equations were found to be signiﬁcant.
pIC50 ¼ 1:510ð0:817Þ5v 0:672ð1:314ÞI1
 1:122ð2:065ÞI2 þ 0:834ð1:560ÞI3  0:780 ð1Þn= 21, R= 0.942, R2 = 0.887, R2A ¼ 0:859, SE = 0.467,
F(4,16) = 31.344, Q= 2.017
pIC50 ¼ 0:766ð0:576Þ4v 0:567ð1:716ÞI1
 1:357ð2:615ÞI2 þ 0:910ð1:986ÞI3 þ 1:679 ð2Þ
n= 21, R= 0.903, R2 = 0.816, R2A ¼ 0:770, SE = 0.595,
F(4,16) = 17.772, Q= 1.518
pIC50 ¼ 0:666ð0:532Þ3v 0:263ð1:891ÞI1
 1:440ð2:712ÞI2 þ 0:894ð3:349ÞI3 þ 0:463 ð3Þ
n= 21, R= 0.895, R2 = 0.802, R2A ¼ 0:752, SE = 0.618,
F(4,16) = 16.182, Q= 1.448
pIC50 ¼ 0:015ð0:012ÞMW 0:540ð1:863ÞI1
 1:199ð2:824ÞI2 þ 0:579ð2:241ÞI3 þ 1:363 ð4Þ
n= 21, R= 0.888, R2 = 0.788, R2A ¼ 0:735, SE = 0.639,
F(4,16) = 14.869, Q= 1.390
pIC50 ¼ 0:096ð0:081ÞMR 0:357ð1:932ÞI1
 2:053ð2:827ÞI2 þ 0:614ð2:233ÞI3  1:604 ð5Þ
n= 21, R= 0.887, R2 = 0.787, R2A ¼ 0:734, SE = 0.640,
F(4,16) = 14.806, Q= 1.386
pIC50 ¼ 6:656ð7:028ÞD 1:169ð1:961ÞI1
 0:634ðpm3:349ÞI2 þ 1:129ð2:388ÞI3  1:545 ð6Þ
n= 21, R= 0.853, R2 = 0.727, R2A ¼ 0:659, SE = 0.726,
F(4,16) = 10.651, Q= 1.174
In all the above models n is the number of data points, R is
correlation coefﬁcient of determination, SE is the standard er-
ror of estimate, R2A represents adjusted R
2 or explained vari-
ance F is variance ratio (Diudea, 2000) between observed
and calculated activity. Q is the quality of ﬁt (Pogliani, 1994;
Pogliani, 1996) and data within parenthesis are for the 95%
conﬁdence intervals.
The positive coefﬁcients of 3v, 4v and 5v, MW, MR and D
in the above models indicate that more bulkier groups with
third, fourth and ﬁfth orders of branching are preferable for
the activity.
The positive sign of coefﬁcient I3 makes it clear that Cl
group at R6 position is beneﬁcial for the activity, while nega-
tive coefﬁcients of I1 and I2 explain that H and –CH2CH3 at
R1 and R2 positions respectively, should be strictly avoided
in future drug modeling.
Predicted and residual values for the best model Eq. (1) are
given in Table 3. In this equation the F ratio value is much
higher than theoretical F value (F(4,16) = 3.01) indicating the
statistical signiﬁcance of this equation. Predicted values are
the calculated activities of the equation and the residual values
are the differences between the observed biological activities
and the calculated activities, which are found to be low.
The plot of observed pIC50 versus predicted pIC50 based on
the Eq. (1) is shown in graph (Fig. 1) and the predicted R2 was
found to be fairly large.3.1. Cross validation
The cross validation analysis was performed using leave one
out (LOO) method (Carmer et al., 1988; Podloga and
Ferguson, 2000), in which one compound is removed from
Table 1 Biological activity, physicochemical data for Bradykinin B1 selective antagonists.
X
R6
R7
NH
R1
OH
R5
R2
R 4
R3
O
S.No. R1 R2 R3 R4 R5 R6 pIC50 R7 X D MR MW
3v 4v 5v I1 I2 I3
1. –CH2– –CH2– H F COOCH3 F 7.228 H H 1.321 81.94 335.3 9.591 6.911 5.147 0 0 0
2. H H H F COOCH3 F 6.287 H H 1.321 81.94 335.3 8.370 6.308 4.964 1 0 0
3. CH3 CH3 H F COOCH3 F 6.903 H H 1.266 91.17 363.3 9.091 6.503 5.052 0 0 0
4. CH2CH3 CH2CH3 H F COOCH3 F 5.962 H H 1.223 100.44 391.4 10.418 7.365 5.207 0 1 0
5. CF3 CF3 H F COOCH3 F 7.022 H H 1.474 92.09 471.3 11.715 8.962 5.401 0 0 0
6. CH3 H H F COOCH3 F 6.180 H H 1.290 86.53 349.3 8.773 6.416 5.011 0 0 0
7. H CH3 H F COOCH3 F 5.978 H H 1.290 86.53 349.3 8.773 6.416 5.011 1 0 0
8. CF3 H H F COOCH3 F 6.962 H H 1.404 86.99 403.3 9.855 7.186 5.213 0 0 0
9. H CF3 H F COOCH3 F 6.319 H H 1.404 86.99 403.3 9.855 7.186 5.213 1 0 0
10. i-Pr H H F COOCH3 F 7.145 H H 1.241 95.76 377.4 9.584 7.003 5.163 0 0 0
11. t-Bu H H F COOCH3 F 7.053 H H 1.222 100.40 391.4 9.855 7.186 5.213 0 0 0
12. i-Pr CH3 H F COOCH3 F 7.078 H H 1.222 100.40 391.4 10.371 7.011 5.183 0 0 0
13. CF3 CH3 H F COOCH3 F 7.610 H H 1.376 91.63 417.3 10.778 7.170 5.227 0 0 0
14. CH3 CF3 H F COOCH3 F 6.237 H H 1.376 91.63 417.3 10.778 7.170 5.227 0 0 0
15. CF3 CH3 H F COOCH3 F 7.610 H H 1.376 91.63 417.3 10.778 7.170 5.227 0 0 0
16. CF3 CH3 H F COOCH3 Cl 9.455 Cl N 1.449 104.15 483.2 11.404 8.155 5.662 0 0 1
17. CF3 CH3 CH3 F
O
N
N
CH3
Cl 9.102 Cl N 1.464 110.28 507.3 12.383 9.315 6.553 0 0 1
18. CF3 CH3 CH3 F
O
N
N
CH3 F 9.180 Cl N 1.449 105.38 490.8 12.383 9.315 6.553 0 0 0
19. CF3 CH3 CH3 F N
N
N
N
CH3 F 9.229 Cl N 1.560 107.85 490.8 12.383 9.315 6.533 0 0 0
20. CF3 CH3 CH3 Cl
N
N
N
N
CH3 F 9.366 Cl N 1.580 112.58 507.3 12.383 9.315 6.533 0 0 0
21. CF3 CH3 CH3 F
N
O
N
CH3 F 9.180 Cl N 1.449 105.38 490.8 12.383 9.315 6.533 0 0 0
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Table 2 Correlation matrix between physicochemical parameters and indicator parameters.
pIC50 D MR MW
3v 4v 5v I1 I2 I3
pIC50 1.000
D 0.725 1.000
MR 0.790 0.475 1.000
MW 0.846 0.821 0.829 1.000
3v 0.830 0.768 0.822 0.965 1.000
4v 0.834 0.805 0.807 0.951 0.954 1.000
5v 0.885 0.768 0.835 0.886 0.886 0.937 1.000
I1 0.433 0.121 0.476 0.396 0.492 0.382 0.313 1.000
I2 0.280 0.312 0.114 0.105 0.026 0.059 0.117 0.091 1.000
I3 0.481 0.269 0.406 0.435 0.331 0.323 0.326 0.132 0.073 1.000
Table 3 Comparison between observed and predicted activ-
ities and their residual values.
S. No. Observed Calculated Residual
1 7.228 6.994 0.234
2 6.287 6.046 0.241
3 6.903 6.850 0.053
4 5.962 5.962 0.000
5 7.022 7.377 0.355
6 6.180 6.788 0.608
7 5.978 6.117 0.139
8 6.962 7.093 0.131
9 6.319 6.422 0.103
10 7.145 7.018 0.127
11 7.053 7.093 0.040
12 7.078 7.048 0.030
13 7.610 7.114 0.496
14 6.237 7.114 0.877
15 7.610 7.114 0.496
16 9.455 8.606 0.849
17 9.102 9.951 0.849
18 9.180 9.117 0.063
19 9.229 9.087 0.142
20 9.366 9.087 0.279
21 9.180 9.087 0.093
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Figure 1 A plot showing comparison between obsevery close to the value of R2 for the entire data set and hence
these models can be termed as statistically signiﬁcant.
Cross validation provides the values of PRESS (predicted
residual sum of squares), SSY (sum of the squares of the re-
sponse) and R2cv (overall predicted ability) and PSE (predicted
squares error) from which we can test the predictive power of
the proposed model. It is argued that PRESS, is a good esti-
mate of the real predictive error of the model and if it is smaller
than SSY the model predicts better than chance and can be
considered statistically signiﬁcant. Furthermore, the ratio
PRESS/SSY can be used to calculate approximate conﬁdence
intervals of prediction of a new compound. To be a reasonable
QSAR model PRESS/SSY should be smaller than 0.4. Also, if
PRESS value is transformed in a dimension less term by relat-
ing it to the initial sum of squares, we obtain R2cv, i.e. the com-
plement to the traces of unexplained variance over the total
variance. The PRESS and R2cv have good properties. However,
for practical purposes of end users the use of square root of
PRESS/N, which is called predictive square error (PSE), is
more directly related to the uncertainty of the predictions.
The PSE values also support our results. The calculated
cross-validated parameters conﬁrm the validity of the models.
All the requirements for an ideal model have been fulﬁlled by
model no. 1, that is why, we have considered it as the best
model.
R2A takes into account the adjustment of R
2. R2A is a mea-
sure of the percentage explained variation in the dependent
variable that takes into account the relationship between theobserved and predicted pIC50 values 
odel 1
y = 0.8868x + 0.8467
R2 = 0.8869
7.5 8 8.5 9 9.5 10
ed pIC50
rved and predicted pIC50 values using model 1.
Table 4 Cross validated parameters and predictive error of coefﬁcient of correlation (PE) for the proposed model.
S. No. Parameters used n PRESS SSY PRESS/SSY R2cv PSE R 1  R2 PE 6PE
1. 5v+ I1 + I2 + I3 21 3.492 27.366 0.128 0.872 0.089 0.942 0.113 0.016 0.096
2. 4v+ I1 + I2 + I3 21 5.669 25.189 0.225 0.775 0.113 0.903 0.184 0.027 0.162
3. 3v+ I1 + I2 + I3 21 6.116 24.742 0.247 0.753 0.118 0.895 0.198 0.029 0.174
4. MW+ I1 + I2 + I3 21 6.542 24.317 0.269 0.731 0.122 0.888 0.212 0.031 0.186
5. MR+ I1 + I2 + I3 21 6.563 24.295 0.270 0.730 0.122 0.887 0.213 0.031 0.186
6. D+ I1 + I2 + I3 21 8.425 22.434 0.376 0.624 0.138 0.853 0.273 0.040 0.240
QSAR based modeling on a series of a-hydroxy amides as a novel class of bradykinin B1 selective antagonists 219number of cases and the number of independent variables in
the regression model, whereas R2 will always increase when
an independent variable is added. R2A will decrease if the added
variable does not reduce the unexplained variable enough to
offset the loss of decrease of freedom.3.2. Predictive error of coefﬁcient of correlation (PE)
The predictive error of coefﬁcient of correlation (PE)
(Chatterjee et al., 2000) is yet another parameter used to decide
the predictive power of the proposed models. We have
calculated PE value of all the proposed models and they are
reported in Table 4. It is argued that if
(i) R< PE, then correlation is not signiﬁcant;
(ii) R> PE; several times (at least three times), then corre-
lation is indicated; and if
(iii) R> 6PE, then the correlation is deﬁnitely good.
(iv) For all the models developed the condition R> 6PE is
satisﬁed and hence they can be said to have a good pre-
dictive power.
4. Conclusions
From the results and discussion made above, it may be con-
cluded that:
(1) Bulkier groups having more branchings should be used
in future drug designing.
(2) The group Cl at R6 position favours the inhibitory
activity.
(3) Groups H and –CH2CH3 at R1 and R2 position respec-
tively, should be avoided in future drug modeling.
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